Top

The European Journal of Health Economics

Published in:

Open Access 01-02-2010 | Original Paper

Cost effectiveness of palivizumab in Spain: an analysis using observational data

Authors: Mark J. Nuijten, Wolfgang Wittenberg

Published in: The European Journal of Health Economics | Issue 1/2010

Abstract

Objectives

To assess the cost effectiveness of palivizumab for prevention of severe respiratory syncytial virus (RSV) disease in high-risk infants in Spain, incorporating country-specific observational hospitalisation data.

Methods

An existing decision tree model, designed using data from a large international clinical trial of palivizumab versus no prophylaxis, was updated to include Spanish observational hospitalisation data. The analysis was performed for preterm children born at or before 32 weeks gestational age, who are at high risk of developing severe RSV disease requiring hospitalisation. Data sources included published literature, official price/tariff lists and national population statistics. The primary perspective of the study was that of the Spanish National Health Service in 2006.

Results

The base-case analysis included the direct medical costs associated with palivizumab prophylaxis and hospital care for RSV infections. Use of palivizumab produces an undiscounted incremental cost-effectiveness ratio (ICER) of €6,142 per quality-adjusted life-year (QALY), and a discounted ICER of €12,814/QALY.

Conclusion

Palivizumab provides a cost-effective method of prophylaxis against severe RSV disease requiring hospitalisation among preterm infants in Spain.

Simoes, E.A.: Respiratory syncytial virus infection. Lancet 354(9181), 847–852 (1999)CrossRef

Canfield, S.D., Simoes, E.A.: Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. Pediatr. Ann. 28(8), 507–514 (1999)

Clark, S., Beresford, M., Subhedar, N., Shaw, N.: Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch. Dis. Child. 83, 313–316 (2000)CrossRef

Groothuis, J.R., Simoes, E.A., Levin, M.J., et al.: Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N. Engl. J. Med. 329, 1524–1530 (1993)CrossRef

The PREVENT Study Group: Reduction of RSV hospitalisation among preterm infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99, 93–99 (1997)CrossRef

The IMpact Study Group: Palivizumab, a humanised respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high risk infants. Pediatrics 102, 531–537 (1998)CrossRef

Carbonell Estrany, X., Quero Jimenez, J.: Comité de Estándares de la Sociedad Española de Neonatología, y Junta Directiva de la Sociedad Española de Neonatología. Recomendaciones para la prevención de la infección por virus respiratorio sincitial. An Esp Pediatr 52(4), 372–374 (2000)

Sigurs, N., Bjarnason, R., Sigurbergsson, F., Kjellman, B.: Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am. J. Respir. Crit. Care Med. 161(5), 1501–1507 (2000)

Sampalis, J.S.: Morbidity and mortality after RSV-associated hospitalisations among premature Canadian infants. J. Pediatr. 143(5 Suppl), S150–S156 (2003)

10.

Joffe, S., Ray, G.T., Escobar, G.J., Black, S.B., Lieu, T.A.: Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 104(3 Pt 1), 419–427 (1999)CrossRef

11.

The European Medicines Agency: http://www.emea.eu.int/index/indexh1.htm, accessed December 2007

12.

Feltes, T.F., Cabalka, A.K., Meissner, H.C., et al.: Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalisation due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr. 143, 532–540 (2003)CrossRef

13.

Bont, L., van Aalderen, W., Kimpen, J.: Long term consequences of respiratory syncytial virus (RSV) bronchiolitis. Paediatr. Respir. Rev. 1, 221–227 (2000)CrossRef

14.

Sigurs, N., Bjarnason, R., Sigurbergsson, F., Kjellman, B., Bjorksten, B.: Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 95, 500–505 (1995)

15.

Simoes, E.A.F., Carbonell-Estrany, X., Kimpen, J., Rieger, C.H.L., Morris, D.D., Pollack, P.F., Groothuis, J.R.: Palavizumab use decreases risk of recurrent wheezing in preterm children. Eur. Respir. J. 24(Suppl 48), 212s (2004)

16.

Nuijten, M.J., Wittenberg, W., Lebmeier, M.: Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 25(1), 55–71 (2007)CrossRef

17.

Lázaro y de Mercado, P., Figueras Aloy, J., Domenech Martinez, E., et al.: The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32–35 weeks in Spain. An Pediatr (Barc) 65(4), 316–324 (2006)CrossRef

18.

Pedraz, C., Carbonell-Estrany, X., Figueras-Aloy, J., Quero, J., IRIS Study Group: Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalisations in premature infants. Pediatr. Infect. Dis. J. 22(9), 823–827 (2003)CrossRef

19.

Nuijten, M.J.C.: Data management in modelling studies: the selection of data sources. Pharmacoeconomics 3(3), 305–316 (1998)CrossRef

20.

Pinto-Prades, J.L., Ortún-Rubio, V., Puig-Junoy, J.: El análisis coste-efectividad en sanidad. Aten Primaria 27, 275–278 (2001)

21.

Simpson, S., Burls, A.: A systematic review of the effectiveness and cost-effectiveness of palivizumab (Synagis^®) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection. A West Midlands Development and Evaluation Service Report Department of Public Health & Epidemiology. University of Birmingham Edgbaston, Birmingham B15 2TT. ISBN No. 0704423219 Copyright, West Midlands Health Technology Assessment Group Department of Public Health and Epidemiology. University of Birmingham (2001)

22.

Instituto Nacional de Estadística (INE).: Datos demográficos básicos, esperanza de vida al nacimiento. Disponible en: http://www.ine.es/(consultado en septiembre de 2005)

23.

Greenough, A., Alexander, J., Burgess, S., et al.: Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch. Dis. Child. 89, 673–678 (2004)CrossRef

24.

Personal communication with Dr P Lázaro y de Mercado: Técnicas Avanzadas de Invetigatión en Servicios de Salud, April 2007

25.

Retribuciones del personal sanitario.: Generalitat de Valencia. Available at http://www.dival.es. (Accessed August 2005)

26.

Carbonell-Estrany, X., Quero, J., Bustos, G., Cotero, A., Domenech, E., Figueras-Aloy, J., Fraga, J.M., Garcia, L.G., Garcia-Alix, A., Del Rio, M.G., Krauel, X., Sastre, J.B., Narbona, E., Roques, V., Hernandez, S.S., Zapatero, M.: Rehospitalisation because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr. Infect. Dis. J. 19(7), 592–597 (2000)CrossRef

27.

Orden 234/2005, de 23 de febrero, del Consejero de Sanidad y Consumo, por la que sefijan los precios públicos por la prestación de los servicios y actividades de naturaleza sanitaria de la Red de Centros de la Comunidad de Madrid. Boletín Oficial de la Comunidad de Madrid (BOCM) núm. 56, 8 de Marzo de, 2005

28.

Bont, L., Aalderen, W.M., Kimpen, J.L.: Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis. Paediatr. Respir. Rev. 1(3), 221–227 (2000)CrossRef

29.

Greenough, A., Cox, S., Alexander, J., et al.: Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch. Dis. Child. 85(6), 463–468 (2004)CrossRef

30.

Instituto Nacional de Estadística (INE).: Contabilidad Regional de España. Available at http://ine.es. (Consulted in January 2006)

31.

Laufer, F.: Thresholds in cost-effectiveness analysis—more of the story. Value Health 8(1), 86–87 (2005)CrossRef

Title: Cost effectiveness of palivizumab in Spain: an analysis using observational data
Authors: Mark J. Nuijten
Wolfgang Wittenberg
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: The European Journal of Health Economics / Issue 1/2010
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-009-0206-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cost effectiveness of palivizumab in Spain: an analysis using observational data

Abstract

Objectives

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

Total or partial knee replacement? Cost-utility analysis in patients with knee osteoarthritis based on a 2-year observational study

Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis

An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis?

The added value of thorough economic evaluation of telemedicine networks

Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach

HTA in Germany: very special and specific